81469a6772
- Source: inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
2.4 KiB
LIXIPARK Trial
Type: Phase 2 randomized controlled trial
Drug: Lixisenatide (GLP-1 receptor agonist)
Indication: Early Parkinson's disease
Status: Completed, published NEJM April 2024
Primary Endpoint: MDS-UPDRS Part III motor score at 12 months — MET (statistically significant)
Design
- N: 156 patients (75 lixisenatide, 75 placebo; some sources report 150)
- Duration: 12 months
- Population: Early Parkinson's disease (<3 years since diagnosis)
- Blinding: Double-blind
- Delivery: Daily subcutaneous injection
Results
Primary Endpoint (12 months):
- Placebo: MDS-UPDRS Part III worsened +3.04 points (disease progression)
- Lixisenatide: Remained at baseline (0 change)
- Between-group difference: Statistically significant
- Interpretation: Lixisenatide halted motor symptom progression over 12 months
Safety:
-
50% of lixisenatide patients: significant GI side effects (nausea, vomiting)
-
1/3 required dose reduction due to GI tolerability
- Safety profile is major practical concern for real-world use
Limitations
- Phase 2 (not Phase 3 — not definitive)
- 12 months (shorter than exenatide Phase 3 at 96 weeks)
- No DaT-SPECT brain imaging to confirm neuroprotection vs symptomatic benefit
- Off-label use NOT recommended pending Phase 3 confirmation
Mechanistic Context
Holscher 2024 review identifies lixisenatide as having "strongest neuroprotective effect" among GLP-1 agonists in clinical trials, correlating with BBB penetrance via adsorption transcytosis. This may explain divergence from exenatide Phase 3 failure, where CSF analysis showed insufficient drug reaching substantia nigra.
Publication
- Journal: New England Journal of Medicine
- Date: April 4, 2024
- DOI: 10.1056/NEJMoa2312323
- Preliminary results: Presented at 2023 International Parkinson and Movement Disorder Society congress, Copenhagen
Follow-up Status
No Phase 3 funding announced as of May 2026. Exenatide Phase 3 failure (Lancet February 2025) may have chilled further GLP-1 Parkinson's trial investment.
Timeline
- 2023-09 — Preliminary results presented at International Parkinson and Movement Disorder Society congress, Copenhagen
- 2024-04-04 — Full results published in NEJM, primary endpoint met with statistical significance
- 2024-2026 — No Phase 3 funding materialized despite positive Phase 2 results